What is Jamjoom Pharma Acretin 0.05 used for?
Jamjoom Pharma's Acretin 0.05% cream is a topical treatment primarily used for skin health. Its active ingredient is tretinoin, a retinoid utilized to treat acne of varying severity, ranging from mild to moderate cases. Beyond its use as an anti-acne medication, Acretin 0.05% is also prescribed to address signs of photo-aging in the skin, such as reducing the appearance of mild wrinkles, fine lines, and other common signs of aging. Due to its potency, users are typically advised to avoid direct sun exposure and to utilize broad-spectrum sunscreen while undergoing treatment with this specific pharmaceutical product.
Related FAQs
Johnson & Johnson Innovative Medicine (its core pharmaceutical division) generates massive annual revenues exceeding $54 billion to $57 billion USD (representing a major share of the healthcare conglomerate's multi-tens-of-billions consolidated top-l...
The pharmaceutical industry in the Kingdom of Saudi Arabia (KSA) is experiencing rapid growth, positioning itself as a major healthcare manufacturing and biotechnology hub within the Middle East and North Africa region.
The ex-dividend date for any given publicly traded security is typically set one business day prior to the official company record date, adhering to modern stock settlement regulations.
Pharmaceutical products and healthcare formulations manufactured under the Jamjoom Pharma brand are utilized by medical practitioners to treat a diverse range of clinical conditions, including cardiovascular disorders, gastrointestinal ailments, and ...
Yes, pharmaceutical stocks contain distinct risk factors that differ from standard consumer or industrial equities.
Jarir Marketing Company (Jarir Bookstore) commands a massive corporate market capitalization of several billion Saudi riyals, reflecting its dominant position as a leading retail and wholesale enterprise specializing in consumer electronics, office s...
Jamjoom Pharma maintains a comprehensive and diverse product portfolio designed to address various healthcare needs.
Evaluating the largest pharmaceutical enterprises by annual sales revenue involves analyzing multinational corporations that command massive market share in innovative medicines, vaccines, and biologics.
Jamjoom Pharma is a multi-specialty pharmaceutical company that provides a broad spectrum of medical treatments across several therapeutic areas.
Jamjoom Pharmaceuticals Factory Company, operating as Jamjoom Pharma, is a leading multinational pharmaceutical enterprise based in Saudi Arabia that develops, manufactures, and markets high-quality generic and branded pharmaceutical products across ...
Equity research analysts covering Jamjoom Pharmaceuticals Factory Company project robust double-digit growth prospects, driven by strong regional demand across key Middle Eastern and African pharmaceutical markets.
Jamjoom Pharmaceuticals Factory Company (Jamjoom Pharma) reports annual revenue turnover scaling past 1.8 billion to over 2 billion Saudi Riyals (approximately $500 million USD).
Jamjoom Pharmaceuticals Factory Company has built a notable dividend track record since its public market debut, establishing itself as a robust player in the Middle Eastern healthcare and pharmaceutical manufacturing sector.
EyePoint Pharmaceuticals anticipates a promising biotechnology future driven by the clinical development of its lead investigational candidate, Duravyu, utilizing the proprietary bioerodible Durasert technology for sustained ocular drug delivery.
Equity research analysts evaluate Jamjoom Pharmaceuticals Factory Company with highly favorable long-term growth prospects, propelled by robust regional demand across key pharmaceutical markets in Saudi Arabia, Egypt, and the wider Middle East and No...
The future of the pharmaceutical industry points toward a highly innovative era defined by personalized medicine, advanced gene therapies, CRISPR-based gene editing tools, and artificial intelligence-accelerated drug discovery pipelines.
The global pharmaceutical industry heading toward 2030 is projected to undergo transformative changes driven by breakthrough advancements in personalized medicine, widespread artificial intelligence integration in drug discovery, and a strategic mark...
Jamjoom Pharmaceuticals Factory Company trades on the Saudi Exchange (Tadawul) under the stock code 4010, anchoring a strong market capitalization within the regional healthcare sector.